- HAPPYneuron will be available for inclusion in Merck’s MSdialog platform for use with Rebif® (interferon beta-1a)
- Agreement provides Merck with exclusive license to cognitive remediation training programs
McKesson announced the launch of its new Drug Spend Intelligence™ tool. Designed by hospital pharmacists, Drug Spend Intelligence is an easy-to-use online tool that provides the information needed to identify purchase trends, evaluate the impact of price fluctuations, and implement and track clinical initiatives. McKesson’s Drug Spend Intelligence provides access to daily data with rich analytics and customizable reports to help identify potential areas for cost containment to lower drug spend and increase savings.
Our vision is to consistently develop individuals and improve overall performance to support Teva in attaining its strategy of business growth. Career development at Teva is therefore considered an essential element and perceived as a shared responsibility of managers, employees and the organization as a whole.
AstraZeneca and the University of Cambridge today announced three new joint schemes to support more than 80 PhD scholarships and eight clinical lectureships over the next five years spanning translational science, basic and clinical research. The programmes reflect the long term commitment of AstraZeneca to the science base in the UK and the shared dedication of the company and the University of Cambridge to developing the next generation of world-class scientists.
The menace of noncommunicable diseases (NCDs) like cardiovascular diseases, diabetes and cancer in the developing world is increasing. These conditions disproportionally affect poverty-stricken areas. Already today 28 million people die each year from these types of diseases in low- and middle-income countries – representing nearly 75% of deaths from NCDs globally.
IMED leader one of 48 new fellows recognised for the advancement of medical science in the UK
Irish drugmaker Shire has signed a merger agreement to acquire US-based NPS Pharmaceuticals for $5.2bn.